Elecoglipron compared with semaglutide for adults with type 2 diabetes
Tests elecoglipron against semaglutide in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Key facts
- Where
- Budapest III, Budapest VIII, Budapest XIII, Debrecen, Salgótarján, Szeged, Szolnok, and Zalaegerszeg, HungarySee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled and who have a higher risk of heart or blood vessel problems.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes for at least 90 days, with HbA1c from 7% (53 mmol/mol) to 10.5% (53 to 91.3 mmol/mol). Increased risk of heart or blood vessel events: heart disease, artery disease, stroke-type disease, heart failure (NYHA II-III), or at least 2 risk factors.
- Earlier treatment
- Diabetes not well controlled with lifestyle changes alone, or with stable treatment with other glucose-lowering medicines. Body weight stable for 90 days before screening.
- Biomarker or test result
- HbA1c from 7% (53 mmol/mol) to 10.5% (53 to 91.3 mmol/mol). Body mass index (BMI) of 23 kg/m2 or more.
Main reasons for not taking part
- Type 1 diabetes or other secondary forms of diabetes
- History of ketoacidosis or hyperosmolar coma
- More than one severe low blood sugar episode in the 180 days before screening
- History of acute or chronic pancreatitis
- Severe heart failure (NYHA IV)
Read by machine on 9 November 2026.
Where in Hungary
- Obudai Egeszseguegyi Centrum Kft.Budapest III, HungaryTaking people
- ClinDiab Kft.Budapest VIII, HungaryTaking people
- Med-Tima Kft.Budapest XIII, HungaryTaking people
- University of DebrecenDebrecen, HungaryTaking people
- Nograd Varmegyei Szent Lazar KorhazSalgótarján, HungaryTaking people
- University of SzegedSzeged, HungaryTaking people
- Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-RendelointézetSzolnok, HungaryTaking people
- Zala Varmegyei Szent Rafael KorhazZalaegerszeg, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662213EU 2025-523933-24-00
- Record updated
- 22 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).Read full original descriptionShow less
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s); HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors; Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (NYHA IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.